Podcasts about orbita

In this episode of The Beat Podcast, host Sandy Vance sits down with Jeff Taylor from Orbita to explore the intersection of operational efficiencies and enhancing patient experience and engagement in healthcare. At Orbita, the team believes these two areas should evolve in parallel, yet many health systems are struggling with isolated, one-off solutions that fail to address the broader challenges their organizations face.In this episode, they talk about:Orbita is transforming the patient experience and improving healthcare interactions.Empowering patients through more involvement in their healthcare, making them feel both more in control and cared for.Achieving up to a 30% reduction in staff inefficiencies by integrating Orbita into healthcare workflows.Breaking down AI concepts, including the difference between machine learning and generative AI, and the importance of safety in implementation.AI allows you to maximize your resources by allowing you to make decisions about where to allocate your team, time, energy, and money for optimal impact.A Little About Jeff:Jeff Taylor is the CEO of Orbita.ai, bringing over 20 years of leadership experience in healthcare IT and business solutions. His expertise in driving growth, operational excellence, and organizational transformation is key to leading Orbita through its next phase of innovation and expansion. Orbita powers virtual health assistants that help healthcare organizations engage patients, improve outcomes, and reduce costs.

Powieść Samanthy Harvey "Orbita" została nagrodzona Bookerem w 2024 roku. To historia, do której autorka bardzo dobrze się przygotowała. Chodź akcja dzieje się w kosmosie, to obserwacje i refleksje bohaterów dotyczą człowieka, życia i ziemskich spraw. W Dwójce o tej pozycji opowiedział Konrad Nowacki z wydawnictwa Wielka Litera.

L'elettronica e la programmazione sono ormai alla base di molte delle innovazioni tecnologiche che ci circondano, ma per anni l'accesso a questi strumenti è stato riservato a pochi professionisti. Arduino ha rivoluzionato questo paradigma, rendendo la tecnologia più accessibile a studenti, appassionati e aziende di tutto il mondo grazie a un approccio open source e a una community in continua crescita. Ma com'è nato questo progetto? E come si è evoluto fino a diventare uno standard tanto nell'educazione quanto nell'industria? Per scoprirlo abbiamo invitato Andrea Richetta, Principal Product Evangelist di Arduino.Nella sezione delle notizie parliamo di Prime Video che lancia il doppiaggio con l'IA e di un nuovo satellite in fase di sviluppo per rilevare detriti spaziali fino a 1 cm.--Indice--00:00 - Introduzione01:34 - Prime Video introduce il doppiaggio con l'IA (DDay.it, Luca Martinelli)02:36 - Un nuovo satellite per rilevare detriti fino a 1 cm (HDBlog.it, Matteo Gallo)04:05 - Arduino: la scheda che ha acceso la passione per l'elettronica (Andrea Richetta, Davide Fasoli, Luca Martinelli)35:26 - Conclusione--Contatti--• www.dentrolatecnologia.it• Instagram (@dentrolatecnologia)• Telegram (@dentrolatecnologia)• YouTube (@dentrolatecnologia)• redazione@dentrolatecnologia.it--Brani--• Ecstasy by Rabbit Theft• One Taste by More Plastic & URBANO

Documental que sigue las historias más importantes del año 2024 a través de las impresionantes imágenes satelitales tomadas desde el espacio por diferentes satélites y que aportan una información única sobre nuestro planeta además de revelar las verdades ocultas detrás de algunos de los titulares del año 2024.

Il music business si è messo alle spalle la crisi di inizio anni 2000. Streaming e musica dal vivo sono più in salute che mai. 

Rasha Al-Lamee and Michael Foley sit down with Mamas Mamas to discuss data on an implantable coronary sinus reducer that can ease symptoms in patients with refractory angina.

Le montagne russe rappresentano un connubio straordinario tra ingegneria, design e narrazione, elementi capaci di trasformare un semplice giro su un tracciato in un'esperienza immersiva e memorabile. Non si tratta solo di velocità e adrenalina, ma anche di precisione tecnica, sicurezza e comfort, elementi fondamentali per rendere ogni corsa emozionante. Vekoma è una delle principali protagoniste di questo settore, con un ruolo di primo piano nella progettazione e produzione di montagne russe nei parchi divertimento di tutto il mondo. Per raccontarci più nel dettaglio questo mondo abbiamo invitato Giacomo Bosso, Product Development Manager di Vekoma.Nella sezione delle notizie parliamo di OpenEuroLLM il large language model finanziato dall'Unione europea e infine del pericolo dei detriti spaziali per l'aviazione civile.--Indice--00:00 - Introduzione01:37 - L'UE avrà il suo LLM, con OpenEuroLLM (AgendaDigitale.eu, Luca Martinelli)02:56 - Il pericolo dei detriti spaziali per l'aviazione (HDBlog.it, Matteo Gallo)04:28 - Vekoma: la tecnologia dietro il brivido delle montagne russe (Giacomo Bosso, Davide Fasoli, Matteo Gallo)58:36 - Conclusione--Contatti--• www.dentrolatecnologia.it• Instagram (@dentrolatecnologia)• Telegram (@dentrolatecnologia)• YouTube (@dentrolatecnologia)• redazione@dentrolatecnologia.it--Brani--• Ecstasy by Rabbit Theft• A New Adventure by JJD (feat. Molly Ann)

Martin Mašek a jeho kometa (4:44 ) – Astronomie: Další zajímavosti o kometě C/2024 Y1 (15:14) – Kosmonautika v roce 2025, 3. část: Orbita, Měsíc a librační body (20:06)Všechny díly podcastu Planetárium můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

Gli speaker di questo episodio Veronica Remondini, Riccardo Rossi, Matteo Deguidi, Gianmarco Vespia, Paolo Amoroso News Europa Clipper è partita [Link] [Link] [Link] [Link] [Link] Spento un altro strumento scientifico a bordo di Voyager 2 [Link] Starship, il volo di IFT-5 [Link] Fast News: la valvola di Peregrine [Link] Fast News: la APU di Ariane 6 [Link] Fast News: la nuova traiettoria di BepiColombo [Link] Rubriche Le storie di Nonno Apollo: La carriera eclettica di Mark Indictor Link della settimana Starship - The game [Link] AstronauticAgenda Versione a griglia, Google Calendar e Timeline La puntata su YouTube https://www.youtube.com/watch?v=3lUxic6d3r0 Sigle e musiche di accompagnamento Sigla iniziale: DHDMusic - We Are One Team (https://www.jamendo.com/track/1862657/we-are-one-team) Sigla finale: Sound Creator - New Electric Waves - Neon World Sound Creator (https://www.jamendo.com/track/1908978/new-electric-waves-neon-world)

Negli ultimi cento anni sono stati registrati circa 10 impatti di asteroidi di dimensioni fortunatamente non così elevate da provocare un'estinzione, ma abbastanza grandi da causare ingenti danni a persone e infrastrutture. Con le moderne tecniche di osservazione e monitoraggio, inoltre, riteniamo di conoscere quasi tutti i corpi celesti più grandi di un chilometro che potrebbero mettere a repentaglio l'esistenza stessa della civiltà umana. Questo tuttavia non preclude la possibilità di poter individuare in futuro un corpo spaziale che potrebbe entrare in rotta di collisione con la Terra. Oltre ad osservare il più possibile il cosmo è quindi fondamentale iniziare ad escogitare metodi altamente tecnologici in grado di interferire con la traiettoria di questi corpi.Nella sezione delle notizie parliamo del Nobel per la fisica conferito agli inventori dell'intelligenza artificiale, di Tesla che ha presentato i Cybercab per il futuro dei taxi a guida autonoma e infine di Ryanair che vuole eliminare completamente il check-in fisico in aeroporto.--Indice--00:00 - Introduzione00:56 - Il Nobel per la fisica agli inventori dell'IA (IlPost.it, Luca Martinelli)02:12 - Tesla presenta il Cybercab per il futuro dei taxi (TheVerge.com, Davide Fasoli)03:35 - La transizione full digitale di Ryanair (DDay.it, Matteo Gallo)05:11 - Come nasce un programma spaziale di difesa planetaria (Matteo Gallo)15:21 - Conclusione--Contatti--• www.dentrolatecnologia.it• Instagram (@dentrolatecnologia)• Telegram (@dentrolatecnologia)• YouTube (@dentrolatecnologia)• redazione@dentrolatecnologia.it--Brani--• Ecstasy by Rabbit Theft• Redemption by Max Brhon

N Engl J Med 2023;389:2319-2330Background: Percutaneous coronary intervention (PCI) does not reduce mortality or myocardial infarction as seen in COURAGE, FAME 2, ISCHEMIA and ISCHEMIA-CKD. However, unblinded studies have indicated that revascularization may improve symptoms, which is a key factor in driving PCI decisions for many patients. ORBITA was the first blinded, placebo-controlled trial of PCI for stable angina and found no significant improvement in exercise time with PCI. The trial had a high use of anti-anginal medications, with an average of 3 medications per patient  pre-randomization. However, this level of medication use is not always achievable in clinical practice due to side effects and challenges with adherence.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.The ORBITA-2 trial sought to test the hypothesis that PCI improves symptoms in patients with stable angina who are not receiving background antianginal medications.Patients: Eligible patients had angina or angina equivalent, severe coronary stenosis of 70% or more in at least one coronary artery and evidence of ischemia on non-invasive testing or by invasive pressure wire assessment.Main exclusion criteria were acute coronary syndrome within 6 months, previous CABG, left main disease, chronic total occlusion of target vessel, and left ventricular ejection fraction of 35% or less.Baseline characteristics: The trial randomized 301 patients – 151 randomized to PCI and 150 to placebo PCI.The average age of patients was 64 years and 79% were men. Approximately 63% had hypertension, 28% had diabetes, 72% had hyperlipidemia, and 62% were current or previous smokers. Left ventricular systolic function was normal in 96% of the patients.Angina class based on the Canadian Cardiovascular Society (CCS) angina grade was 2 in 58% of the patients and 3 in 39%. Approximately 80% had single vessel disease, 17% had 2-vessel disease and 2% had 3-vessel disease. Left anterior descending coronary artery was the target vessel in 55% of the patients.Procedures: Patients initially underwent coronary angiogram and invasive physiologic assessment was performed in each vessel with 50% or more stenosis. Patients underwent the coronary angiography while wearing headphones with music playing for auditory isolation throughout the procedure. Patients who had evidence of ischemia in at least one territory were then randomized in a 1:1 ratio to PCI or placebo PCI. Patients were sedated until they were unresponsive to verbal and tactile stimuli. In the PCI group, all target vessels were treated during the index procedure. Patients in the placebo group did not receive intervention and were kept sedated for at least 15 minutes after randomization.The recovery room staff and all subsequent medical providers were unaware of the treatment assignments. The operator and research staff who were present during the randomization procedure had no further contact with the patients.Anti-anginal medications were stopped at enrollment. Antihypertensive medications that has antianginal properties were replaced with different agents.Patients were followed up for 12 weeks during which they reported daily angina symptoms using a smart phone application. New anti-anginal medications or increase in the dose of anti-anginal medications were also tracked. At the end of the 12 weeks, patients completed symptom and quality-of-life questionnaires, had an assessment of CCS class, and underwent a treadmill exercise test and dobutamine stress echocardiography. After all of these were completed, patients and medical staff were unblinded.Endpoints: The primary endpoint was an angina symptom score calculated based on the number of angina episodes that a patient reported on a given day and the number of units of antianginal medication prescribed on that day. In this score, each episode of angina on a particular day counts as 1 point for a maximum of 6 points per day (0 points given to no angina), and each unit of anti-anginal medications counts as 7 points (0 points given for no antianginal medications prescribed that day). In supplement table 3, authors provided what counted as one unit of anti-anginal medications. For example, atenolol 25 mg counted as 1 unit and amlodipine 2.5 mg counted as one unit.Secondary endpoints included frequency of angina, use of ant-anginal medications, exercise time on treadmill test and symptoms questionnaires.Analysis was performed based on the intention-to-treat principle. The estimated sample size to achieve 80% power at 0.05 alpha was 284 patients. This is based on assumed standard deviation of 6 angina symptom score units and a difference of 2 units between PCI and placebo.Results: Data were available on 99.7% of the total patient-days.Compared to placebo, PCI reduced the mean angina symptom score (2.9 vs 5.6, OR: 2.2, 95% CI: 1.4 - 3.5; p

For full review of the trials, please visit https://cardiologytrials.substack.com/ Get full access to Cardiology Trial's Substack at cardiologytrials.substack.com/subscribe

Surgical clearance, NICM assessment, dueling perspectives on PCI as first-line therapy for angina, GDMT in HFrEF are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. New ACC Peri-operative Guidelines Released ACC Guideline document https://www.jacc.org/doi/10.1016/j.jacc.2024.06.013 J Vasc Surg https://www.jvascsurg.org/article/S0741-5214(21)00335-9/fulltext McFalls and colleagues; CARP https://www.nejm.org/doi/full/10.1056/NEJMoa041905 II. NICM – We may be doing it wrong in Selecting ICDs JAMA Meta-analysis https://jamanetwork.com/journals/jama/fullarticle/2823869/ German CMR ICD Trial https://www.clinicaltrials.gov/study/NCT04558723 BRITISH CMR trial https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/britishusing-cmr-scar-as-risk-indication-tool-in-nicm-and-severe-lvsd/ III. When Should PCI be Used in Chronic Stable CAD?   Rajkumar and Al-Lamee; PCI First https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.124.011201   Boden and De Caterina; Meds First https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.124.011268 ORBITA 10.1016/S0140-6736(17)32714-9 ORBITA 2 trial https://www.nejm.org/doi/full/10.1056/NEJMoa2310610 IV. GDMT Underuse in HFrEF Greene and colleagues https://doi.org/10.1016/j.jchf.2024.08.002 DAPA HF https://www.nejm.org/doi/full/10.1056/NEJMoa1911303 RALES https://www.nejm.org/doi/full/10.1056/NEJM199909023411001 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

The Lancet Volume 391, Issue 10115, 6–12 January 2018, Pages 31-40Background:  For decades, cardiologists commonly used percutaneous coronary intervention (PCI) for the relief of angina. It made sense because PCI resulted in near complete resolution of blood flow through a stenosed vessel. The problem facing evidence-based clinicians was that no previous trial had compared PCI to a placebo (sham) procedure. Instead, previous trials had compared PCI (a procedure) to tablets. In the absence of blinding, a procedure will exert a larger placebo effect than tablets.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber.The Objective Randomized Blinded Investigation with optimal medical Therapy of Angioplasty in stable angina (ORBITA) trial was designed to assess the effect of PCI versus placebo on exercise time in patients with stable ischemic symptoms.ORBITA met ethical criteria because previous trials, primarily the COURAGE trial, had found that PCI in addition to medical therapy did not reduce hard outcomes, such as myocardial infarction or death due to cardiovascular causes, compared to medicine alone. In other words, PCI in patients with stable coronary artery disease was not a disease-modifying therapy; it was used to relieve symptoms.Patients:  Patients had to have single-vessel coronary artery disease (≥ 70% stenosis) that was appropriate for PCI and angina or equivalent symptoms. The authors published in the appendix pictures of every patient enrolled in the trial. Exclusion criteria included acute coronary syndrome, previous bypass surgery, left main stenosis, chronic total occlusions, severe valvular disease or left ventricular dysfunction, moderate or severe pulmonary hypertension, or life-expectancy less than 2 years.  Baseline Characteristics: The mean age of patients was 65 years. More than 79% were male. Almost 90% had normal left ventricular function. Canadian Cardiovascular Society class included about 60% with class 2 symptoms and nearly 40% with class 3 symptoms. Angina had been present for a mean of 9 months. Trial Procedures: ORBITA had two phases. First was a 6-week medical optimization phase wherein patients were optimally treated with medical therapy. They had a questionnaires, dobutamine stress echo, and a cardiopulmonary exercise test.  They then had the blinded procedure with either PCI or placebo.All PCI was done with drug-eluting stents. The procedure included measures to insure blinding, such as headphones during the procedure, sedation and a measure of hemodynamics such as fractional flow reserve. The second phase was a 6-week period of blanking in which patients underwent follow-up assessment. Testing procedures were similar to the pre-procedure protocol.At all times, the staff were blinded to the procedural data. This included procedural details as well as post-procedural assessment. The recovery staff were well rehearsed in their role of maintenance of blinding. Patients and subsequent medical caregivers were also blinded to treatment allocation. The study physicians present during the procedure had no further contact with the patient during the study.By the time of randomization, in the PCI group, 103 (98%) of 105 patients were taking aspirin, 103 (98%) were taking a second antiplatelet, and 99 (94%) were taking a statin, compared to 93 (98%), 94 (99%), and 91 (96%) of 95 patients, respectively, in the placebo group. At the same timepoint, in the whole study population, 156 (78%) of 200 patients were taking β blockers and 182 (91%) were taking calcium channel antagonists.The mean number of antianginal medications in the PCI group was 0·90 (SD 0·8) at enrollment, 2·8 (1·2) at pre-randomization, and 2·9 (1·1) at follow-up, compared to the placebo group in which the mean number of medications was 1·0 (0·9; p=0·357), 3·1 (0·9; p=0·097), and 2·9 (1·1; p=0·891), respectively.Endpoints: The primary endpoint of ORBITA was the difference between PCI and placebo groups in the change in treadmill exercise time. The power calculation relied on previous trials wherein PCI had resulted in a 48-55 second increase in exercise time over medicine. ORBITA authors designed the trial to detect a 30 second increase in exercise time.They estimated that a sample size of 100 patients per group had more than 80% power to detect a between-group difference in the increment of exercise duration of 30 seconds, at the 5% significance level, using the two-sample t test of the difference between groups. This calculation assumed a between-patient standard deviation of change in exercise time of 75 s. Since there had been no previous placebo-controlled trials of PCI, the authors initially allowed for a one-third dropout rate in the 6-week period of medical optimization between enrollment and randomization and therefore planned to enroll 300 patients. But the dropout rate was much lower, so only 230 patients had to be enrolled. The primary endpoint was continuous, and it was calculated as a difference between groups. They also measured secondary endpoints, including measures of angina severity and quality of life.Results: A total of 368 patients were screened for eligibility, and 200 were randomly assigned. Most were excluded from randomization because they declined to participate. There were 105 allocated to PCI (all but one had PCI) and 95 to placebo (4 patients had PCI due to a procedural complication).Across all patients, the mean area stenosis by quantitative coronary angiography was 84·4% (SD 10·2), mean FFR was 0·69 (0·16), and mean iFR was 0·76 (0·22). 57 (29%) patients had FFR greater than 0·80 and 64 (32%) had iFR greater than 0·89.The median length of stent implanted was 24 mm (IQR 18–33). After PCI, the mean FFR improved to 0·90 (SD 0·06; p

ORBITA2-Symptoms: The Symptom-Stratified Analysis of ORBITA-2

Quale fattore è alla base del dominio di Pecco ad Assen? Sono tante le Ducati, altre tre 2024 e pure le 23 che qualcuno riesce a sfruttare a dovere. Allora vediamo quanto giocano, per il successo, le qualità del campione del mondo e quelle della sua super squadra.  Assen resta l'università della moto? Sì, e mostra tante realtà: l'Aprilia che funziona molto bene ma raccoglie poco, la KTM che ha ancora qualche area da sistemare, la Yamaha che resta un passo indietro (ma si rinforza dal 2025 con Pramac), la Honda che brancola del buio... La penalità a Marquez? Correre sul filo della pressione minima ha condizionato la sua gara. Marc pareva da podio, ha guidato "sulle uova"e la penalizzazione di ben 16" (per 0,001 bar...) lo ha messo fuori gioco. Errore suo o della squadra? Forse, secondo qualcuno, sarebbe da sanzionare il regolamento... Chiariremo la regola e indagheremo sulle varie polemiche. Poi le altre due gare, gli aggiornamenti sulle condizioni di Rins e di Espargaro, infine i pronostici per la Germania. Perché si corre subito al Sachsenring e lo Zam è già in sella alla sua moto...

Minare le comunicazioni dei nemici privandole del supporto dei satelliti, un vantaggio strategico importante, una guerra nella guerra che interessa da vicino il conflitto in Ucraina definito da alcuni analisti militari la prima ‘Space war' della storia.ISCRIVITI E SEGUI NOTIZIE DALL'UCRAINA:   YouTube: https://bit.ly/3FqWppn     Spreaker: https://bit.ly/42g2ONG   Apple Podcasts: https://apple.co/3JE1OMi   Spotify: https://spoti.fi/40bpm0v   Google Podcasts: https://bit.ly/3lfNzUy   Amazon Podcast: https://amzn.to/40HVQ37 Audible: https://bit.ly/4370ARc    I PODCAST ADNKRONOS:   Fa notizia da 60 anni: https://www.adnkronos.com/speciali/adnkronos60_podcast/ Aggiungi contatto: https://www.adnkronos.com/speciali/aggiungi_contatto/   Notizie dall'Ucraina: https://www.adnkronos.com/speciali/notizie_ucraina/     Israele sotto attacco: https://www.adnkronos.com/speciali/israele_sotto_attacco/  Le Storie, La Storia: https://www.adnkronos.com/speciali/le_storie_la_storia/    Sanremo Express: https://www.adnkronos.com/speciali/sanremo_podcast_2024      RESTA IN CONTATTO CON NOI:   https://www.adnkronos.com/      https://twitter.com/Adnkronos      https://www.facebook.com/AgenziaAdnKronos      https://www.instagram.com/adnkronos_/ 

Coronary Sinus Reducer for the Treatment of Refractory Angina: A Randomized, Placebo-Controlled Trial (ORBITA-COSMIC)

Witam Państwa, nazywam się Jarosław Drożdż, pracuję w Centralnym Szpitalu Klinicznym Uniwersytetu Medycznego w Łodzi, skąd nagrywam podcast Kardio Know-How. W tym odcinku kontynuuję omawianie doniesień z kongresu ACC.Szczegółowy TRANSKRYPT do odcinka.Podcast jest przeznaczony wyłącznie dla osób z profesjonalnym wykształceniem medycznym.

Roberto Iuppa lavora negli ambiti della ricerca sperimentale in fisica e astrofisica, con una passione particolare per il settore spaziale. Nonostante la sua giovane età, ha già maturato una significativa esperienza nella divulgazione scientifica e nell'innovazione tecnologica. Dedica una parte importante del suo lavoro a ispirare e formare le nuove generazioni su temi legati all'esplorazione spaziale e alle potenzialità future di questo campo. Con un background solido in fisica e astrofisica, Roberto ha collaborato con numerose istituzioni e organizzazioni per promuovere l'educazione spaziale. Nel podcast "I lavori di domani", ha contribuito condividendo la sua esperienza e visione sulle opportunità emergenti nel settore spaziale, illustrando come queste influenzeranno il mondo del lavoro nei prossimi decenni.Siti, app, libri e link utiliUniversità di Trento linkedinEuropean Space Agency (ESA)Il sito web dell'Università degli Studi di TrentoSito web EsaSito web AsiUltime notizie su esplorazione spaziale, innovazione, autonomiaSito web Istituto Nazionale di fisica NucleareI libri da scegliereLa formazione in scienza spazialeIl ricercatore in ambito spaziale studia i fenomeni dell'universo e sviluppa tecnologie per l'esplorazione spaziale. Le sue attività includono la conduzione di esperimenti, l'analisi dei dati raccolti e la collaborazione con ingegneri per progettare nuovi strumenti e veicoli spaziali.

Polska firma PIAP Space, lider w dziedzinie robotyki kosmicznej, zakończyła projekt ORBITA, którego celem jest zwiększenie użyteczności i efektywności obsługi satelitów przez wprowadzenie chwytaków przeznaczonych do użycia na manipulatorach robotycznych na orbicie. Zaproponowane w ramach programu rozwiązanie umożliwi prowadzenie regularnych misji konserwacyjnych i naprawczych w trudnym środowisku kosmicznym. To klucz do oszczędności i szansa przedłużania czasu działania satelitów albo strącania z orbity kosmicznych śmieci. Jak mówi RMF FM kierownik projektu ORBITA Andrzej Jakubiec, PIAP Space uczestniczy w finansowanym przez Komisję Europejską projekcie EROSS IOD, który w 2027 roku ma pokazać możliwości serwisowe na orbicie. Istotną rolę będzie miał do wykonania opracowany przez Polaków chwytak LARIS.

ACC.24: ORBITA-COSMIC

Christopher Rajkumar, Rasha Al-Lamee, and C. Michael Gibson discuss this randomized trial of PCI versus a placebo procedure for stable angina.

AI has seen rapid adoption in health systems, but are we ready for it? In this episode, hosts Reed Smith and Chris Boyer discuss the challenges with adopting federal regulation on AI and how local organizations can begin developing an AI governance framework. Patty Riskind, CEO of Orbita, joins to share her perspectives on responsible AI adoption in health systems.   Mentions from the Show: Healthcare startups are rushing to sell AI to hospital systems. But a new survey suggests many simply aren't ready for it. Artificial intelligence is making critical health care decisions. The sheriff is MIA. 5 best practices for AI governance: Building a culture for responsible - Fast Company Building an AI Governance Framework Patty Riskind on LinkedIn https://orbita.ai/ Learn more about your ad choices. Visit megaphone.fm/adchoices

La decisione di piazzare armi nucleari nello spazio da parte della Russia è una minaccia per l'inytero Occidente

This Ukrainian ghost town wasn't as abandoned as I thought by RedHotOwl 0:00 - 15:53 Black Cab by Christopher Haynes 15:53 - 41:38 Author Credits: https://www.reddit.com/r/nosleep/comments/kn2bbu/this_ukrainian_ghost_town_wasnt_as_abandoned_as_i/ https://www.reddit.com/user/RedHotOwl/ https://www.creepypasta.com/black-cab/ --- Send in a voice message: https://podcasters.spotify.com/pod/show/themisterdavis/message

As many of you know, I have long argued (unsuccessfully until now) for a placebo-controlled trial of AF ablation. One group gets the ablation; the other gets a placebo or sham procedure. This way we can sort out the placebo-resistant effect of the ablation. Finally, here is the first report of one. Dr. Malcolm Finlay is an electrophysiologist at St Bartholomew hospital in London UK and primary investigator of the study. They recently published their feasibility study for AF ablation vs placebo. The American Heart Journal published the pilot study of 20 patients. Finlay and colleagues call it the ORBITA AF trial. But it's important to note that this was done separate from the ORBITA investigators at Imperial College. The larger study will have a different name. Here is a copy and paste:Twenty patients with PersAF (duration

In this week's Parallax, Dr Ankur Kalra welcomes back Dr Sukhjinder Nijjer for their much-anticipated annual review of advancements in cardiovascular medicine that defined the year 2023. Dr Nijjer, a Consultant Cardiologist in the UK, serves as the President of the Royal Society of Medicine and is an Honorary Senior Clinical Lecturer at Imperial College London. Drs Kalra and Nijjer share their perspectives and experiences, offering valuable insights, practical tips and considerations when interpreting this year's most impactful trials: • ORBITA-2 (AHA Scientific Sessions): PCI for stable angina • FIRE (ESC Congress): Functional versus culprit-only revascularization in elderly patients with myocardial infarction and multivessel disease • DAPA-MI (AHA Scientific Sessions): SGLT2i in MI without diabetes or heart failure • ILUMIEN IV (ESC Congress): OCT vs angiography-guided PCI • OCTOBER (ESC Congress): OCT or Angiography Guidance for PCI in Complex Bifurcation Lesions • ARTESIA (ESC Congress): Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation • SELECT (AHA Scientific Sessions): Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes What are the most impactful cardiovascular trials of 2023? How do Dr Kalra and Dr Nijjer integrate the latest information into their daily practices?

For this year's review, Bob Harrington and Mike Gibson revisit the major cardiology conferences -- from ACC in New Orleans to AHA in Philly. This podcast is intended for healthcare professionals only. To read a transcript or to comment, visit: https://www.medscape.com/author/bob-harrington ACC 2023 Top Trials - Bempedoic Acid Cuts CV Events in Statin-Intolerant Patients: CLEAR Outcomes https://www.medscape.com/viewarticle/989100 - Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients - Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616 https://www.jacc.org/doi/10.1016/j.jacc.2023.02.018 ACC/WCC 2023 Collection Page https://www.medscape.com/viewcollection/36966 ESC 2023 Top Trials - Wegovy Scores HFpEF Benefits in People With Obesity https://www.medscape.com/viewarticle/995844 - Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity https://www.nejm.org/doi/full/10.1056/NEJMoa2306963 - Acoramidis Shows Encouraging Results in ATTR Cardiomyopathy https://www.medscape.com/viewarticle/995883 ESC 2023 Collection Page https://www.medscape.com/viewcollection/36988 AHA 2023 Top Trials - Semaglutide 'A New Pathway' to CVD Risk Reduction: SELECT https://www.medscape.com/viewarticle/998373 - Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes https://www.nejm.org/doi/full/10.1056/NEJMoa2307563 - Bariatric Surgery is Associated With Improved Coronary Microvascular Function and Cardiorespiratory Fitness in Patients With Ischemia and Non-Obstructive Coronary Arteries https://www.ahajournals.org/doi/10.1161/circ.148.suppl_1.18949 - Angioplasty Finally Proven Beneficial in Stable Angina: ORBITA-2 https://www.medscape.com/s/viewarticle/998375 - A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina https://www.nejm.org/doi/full/10.1056/NEJMoa2310610 - Impressive Bleeding Profile With Factor XI Inhibitor in AF: AZALEA https://www.medscape.com/viewarticle/998418 - Promising First Results With DNA Editing to Lower LDL https://www.medscape.com/s/viewarticle/998719 - Single Injection Reduces Blood Pressure for 6 Months: KARDIA-1 https://www.medscape.com/viewarticle/998666 AHA 2023 Collection Page https://www.medscape.com/viewcollection/37277 Other Mentions - N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects https://www.nejm.org/doi/full/10.1056/NEJMc2031173 - Rimonabant: From RIO to Ban https://doi.org/10.1155%2F2011%2F432607 - Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial https://doi.org/10.1016/S0140-6736(17)32714-9 - Asundexian Phase 3 AF Study Halted for Lack of Efficacy https://www.medscape.com/viewarticle/998665 - Challenges in the Design and Interpretation of Noninferiority Trials https://www.nejm.org/doi/full/10.1056/nejmra1510063 - Milvexian for the Prevention of Venous Thromboembolism https://www.nejm.org/doi/full/10.1056/NEJMoa2113194 You may also like: Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine Hear John Mandrola, MD's summary and perspective on the top cardiology news each week, on This Week in Cardiology https://www.medscape.com/twic Questions or feedback, please contact news@medscape.net

TLM - Em 2016 los astrónomos descubrieron un objeto que, habiendo salido de la Luna, se ha convertido en un "cuasi satélite natural de la Tierra". En este episodio nos ocupamos de los "otros" satélites de la Tierra. Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

AHA23 Congress Coverage: PCI for Stable Angina (ORBITA-2 Trial)

This episode focuses on the impact of Artificial Intelligence in the healthcare sector. We  explore how AI is improving patient experiences and streamlining healthcare processes. My guest, Patty Riskind, CEO of Orbita,  discusses her journey in the healthcare industry and the experiences that have influenced her leadership approach.Patty explains the role of generative and conversational AI in healthcare, examining its contribution to more empathetic patient interactions and its role in reducing administrative tasks for healthcare providers. We discuss advancements in AI-driven product development, particularly in speeding up chatbot deployment. The capabilities of virtual healthcare assistants, including appointment scheduling and post-visit follow-ups, are also covered.Support the showHost David E. Williams is president of healthcare strategy consulting firm Health Business Group. Produced by Dafna Williams.

An AHA Recap: SELECT, ORBITA2, and ARTESIA are the trials John Mandrola, MD, reviews in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic American Heart Association 2023 on theHeart.org | Medscape Cardiology https://www.medscape.com/viewcollection/37277 I. SELECT Trial Semaglutide 'A New Pathway' to CVD Risk Reduction: SELECT https://www.medscape.com/viewarticle/998373 Positive Results From SELECT Begins a New Era in Cardiology https://www.medscape.com/viewarticle/998217 Is It Time for Cardiologists to Treat Obesity? https://www.medscape.com/viewarticle/998391 - SELECT trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307563 - SUSTAIN 6 https://www.nejm.org/doi/full/10.1056/nejmoa1607141 II. ORBITA 2 Angioplasty Finally Proven Beneficial in Stable Angina: ORBITA-2 https://www.medscape.com/s/viewarticle/998375 ORBITA-2 Saves Interventional Cardiology and Challenges Current Guidance https://www.medscape.com/viewarticle/998213 PCI, the Antianginal 'Pill': ORBITA-2 in Detail https://www.medscape.com/viewarticle/997777 - ORBITA-2; NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2310610 - ORBITA 1 https://doi.org/10.1016/S0140-6736(17)32714-9 III. ARTESIA Apixaban Cuts Stroke but Ups Bleeding in Subclinical AF: ARTESIA https://www.medscape.com/viewarticle/998379 Sadly, ARTESIA Doesn't Answer a Common Question in Cardiology https://www.medscape.com/viewarticle/998215 - NOAH https://www.nejm.org/doi/full/10.1056/NEJMoa2303062 - ARTESIA https://www.nejm.org/doi/10.1056/NEJMoa2310234 - AVERROES https://www.nejm.org/doi/full/10.1056/NEJMoa1007432 - McIntyre Meta-analysis https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.067512 - TRENDS https://www.ahajournals.org/doi/10.1161/circep.109.849638 - ASSERT https://doi.org/10.1093/eurheartj/ehx042 You may also like: Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Digital health expert Patty Riskind (CEO, Orbita) digs into three main barriers physicians may perceive in incorporating chatbots into their practice. Virtual assistants, such as chatbots, have changed the way businesses operate, and how people navigate their day-to-day tasks. From making travel plans to scheduling car services, digital tools are improving consumer access while conserving staff resources, but the medical world has been falling behind.Also, Marc Bonaca, MD, MPH (University of Colorado), discusses the first 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. A critical step in the Biden administration's attempt to drive down the high cost of prescription drugs for older people. While Medicare wields enormous power over the costs of other aspects of medical care, dictating how much doctors and hospitals can be paid for medical services, it has been barred from negotiating drug costs. That will change next year, when Medicare for the first time will be able to directly haggle with drug-makers over prices for the costliest medications. The negotiated prices will go into effect in 2026.Enjoy listening!Let us know what you thought of this week's episode on Twitter: @physicianswkly Want to share your medical expertise, research, or unique experience in medicine on the PW podcast? Email us at editorial@physweekly.com! Thanks for listening!

S1E11: Join host Jared Johnson and guest Patty Riskind, CEO of Orbita as they discuss how to "slay the dragons of doubt" about healthcare chatbots and virtual assistants. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio.” Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Host Matt Fisher is joined by Bill Rogers, President and Chairman at Orbita. They discuss the historical development of telehealth; evolution of artificial intelligence; what is meant by artificial intelligence; impact of GPT; model for helping efficiency and promoting deeper understanding; recognition of risk and ability to account for potential issues. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio.” Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Questa sera con lo Zam, Bernardelle e Nico la nostra analisi partendo da Marco Bezzecchi: il successo era nell'aria, la Ducati è promossa a pieni voti, Zarco e Alex Marquez entusiasmano, pesa l'errore di Bagnaia. C'è tanto da capire, allargando l'esame al recupero sorprendente di Morbidelli, alla KTM che sabato pare una moto e la domenica un'altra, all'Aprilia che dopo un super venerdì finisce nelle retrovie. Mentre la Honda naufraga senza il 93. Poco grip sull'asciutto (Quartararo paga dazio), eppure le gomme rain di Michelin esaltano la pista argentina con la pioggia. Come si spiega? Spazio anche alle altre gare e agli italiani protagonisti: Arbolino vincitore della Moto2 e Migno sul podio della Moto3. Non perdete l'appuntamento di questa sera alle 18, qui e sul canale YouTube di Moto.it e preparate le vostre domande!

As space enthusiasts and entrepreneurs look to expand human civilization to the Moon, Mars, and beyond, few stop to examine the geopolitical risks of space colonization or the opportunity costs of not fixing problems on Earth. While most Faster, Please! guests advocate further expansion into space, Daniel Deudney offers a different perspective. Deudney is a professor of political science, international relations, and political theory at Johns Hopkins University. He's the author of several books, including Dark Skies: Space Expansionism, Planetary Geopolitics, and the Ends of Humanity, released in March of 2020.This interview was first released in June 2021 for my AEI podcast, Political Economy, and now I'm sharing it with subscribers to Faster, Please! (Unfortunately, our chat preceded my viewing and reading of The Expanse, which does a great job suggesting Deudney's concerns.)In This Episode* Space expansionism and its dangers (1:24)* Space infrastructure (13:57)* Hedging existential risk (18:13)* Principles for space policy (30:40)Below is an edited transcript of our conversation.Space expansionism and its dangersJames Pethokoukis: My listeners love when I read during these podcasts. I'm going to start by reading two quotes. The first quote is from Elon Musk:“You want to wake up in the morning and think the future is going to be great – and that's what being a spacefaring civilization is all about. It's about believing in the future and thinking that the future will be better than the past. And I can't think of anything more exciting than going out there and being among the stars.”Quote two is from the Blue Origin website:“Blue Origin was founded by Jeff Bezos with the vision of enabling a future where millions of people are living and working in space to benefit Earth. In order to preserve Earth, Blue Origin believes that humanity will need to expand, explore, find new energy and material resources, and move industries that stress Earth into space.”Now, I think you would probably call both those visions “space expansionist”. But that is not your vision, right? So what don't you like about those visions?Daniel Deudney: Well, Musk and Bezos articulate a vision of space expansionism that was first articulated early in the 20th century and has been subsequently developed. Bezos was actually a student of Gerard O'Neill, who was one of the main visionaries of space colonization in the United States during the 1970s. So they're articulating a central set of ideas that is held by a large number of people, both in the United States and globally. And my book, Dark Skies, is really a systematic evaluation of the actual impact of space activities to date and a critical assessment of the likely impacts of many of these yet unrealized projects.So to start with the historical record, this is not a simple task because space is just a place. And so there's a heterogeneity of activities that have gone on there. So it's like summing up apples, light bulbs, and grenades. But the standard narrative of space activities to date, I argue, is woefully inaccurate. It leaves out one of our major space programs — and, depending on how you count, perhaps our major space program and arguably our most consequential space program — which is the use of ballistic missiles to deliver thermonuclear weapons at global distances in very short periods of time.The standard definition of space weapons is that they are weapons used against objects in orbit or placed in orbit. That's completely insufficient because it leaves out the use of the frictionless environment of space as a corridor for rapid bombardment at distance. And so I say that we have this major space program that we don't acknowledge as a space program. It's what would be called an “unknown known.” Everyone knows that these exist, but they get misplaced or miscategorized. And if we put ballistic missiles back into the ledger sheet for an assessment of space activities to date, I have to conclude that the impact has been to increase the probability of nuclear war, which would obviously be a civilizational, perhaps existential, catastrophe for humanity. Take the Cuban Missile Crisis. The fact that these weapons move so rapidly — are so difficult to intercept — has created this unprecedented situation of vulnerability.And this really points to a more general fallacy of this very optimistic thinking about space, which is to simply neglect the violence potential and the tendencies for this violence potential to be harnessed. It's like they think that space is good, and if something is not good, then it can't be involved in space. The reality is that this major space program (that we don't acknowledge as such) has been a major negative in terms of the survival of our civilization. And so the first step for the space expansionist, I think, is really to be a bit more realistic and accurate about what they've actually done and the inherently enormous violence potential involved in this domain.Is that your primary critique then? I mean, those are two very attractive visions. And is your main critique that they are just utterly ignoring how it could all go wrong? That they're only viewing this as creating a space economy, creating space hotels, creating lunar or Mars colonies, or deflecting asteroids — but they're ignoring how all these technologies could be used for ill?Yeah, that's a general summation. The first key point is the ballistic missiles and space weapons. And then, looking at the larger future set of agendas that they advocate, colonization sits really at the center of it — millions, billions, or trillions of people living in space to make humanity a multi-planetary species. And their seemingly ace-in-the-hole argument is that the Earth is fragile — it's vulnerable, it's subject to all sorts of disasters. And therefore, we need to get all of our eggs out of this one frail basket.Seems like a good argument.At its surface, it does. And as they say, the reason the dinosaurs went extinct is because they didn't have a space program.So let's look at what would be entailed in humanity becoming a multi-planetary species: colonization of Mars, colonization of asteroids, and so forth. This would almost certainly produce an interstate anarchy. The assumption that the advocates make, and I think it's well-founded, is that any colony which is big enough to provide existential risk insurance will be big enough to become politically independent. And once it becomes politically independent, we have to expect the same types of dynamics that have been characteristic of Earth history and interstate anarchy.Then we read the terrain, and we see immediately that it's got this inherently enormous violence potential. And that's because these objects — asteroids, even space debris — are moving so rapidly. The reason these asteroids are so destructive when they strike the Earth is not because of their mass, but because of their mass combined with their velocity. And so this is an environment that is inherently far more violent than any environment that we have dealt with on the Earth.So I asked the question: What is going to be the likelihood that we'll have — as we have on Earth — wars and violent rivalries in what I call the Solar Archipelago? One factor, of course, would be the issues of mutual vulnerability, which I argue would be extremely high. The ratio of destructive capacity, like on Earth with nuclear weapons, is going to greatly exceed the territorial, habited locations. So saturation of violence capacity will mark solar-orbital space. Even though, of course, there will be a recovery of distance — it won't all be quick because Mars is tens of millions of miles away, at least.Then you asked the question about rivalries over frontier resources. The historical record on Earth is that frontiers are very violent places. Rivalries for making claims will be very likely. So we have a war-prone argument there.Another factor: To what degree are the units like one another? On Earth, we think that units that are like one another — particularly if they are democracies — are less war-prone towards one another, and I think that colonies in space are likely to become very different than places on Earth. The advocates all say this. It seems intuitively obvious. And the most important difference that will invariably emerge will be a very fundamental one: biological species radiation. This is to say that the human species will start branching. This will occur inevitably, slowly, through processes of Darwinian evolution. But many of the advocates insist that we will do this more quickly with genetic engineering.And so it's not only that we're going to have multiple bodies in the solar system inhabited, they will be inhabited over time, almost inevitably, by intelligent species — at least as intelligent as us, with at least our levels of technology. But they will be radically different in their biological character than humans on the Earth.Look at all of the violence which has been sparked and justified by minor cosmetic skin-color differences on Earth, and think about what would happen if we have really different species. Let your imagination go here. The biological potentials for variation are enormous. It might well be that insectoid body forms will prove more appealing in space environments.And so we will have eventually a solar system that will be inhabited by aliens, but they will be descendants of Earthlings. And that to me is a very unappealing future. And I think that it's almost an inevitable one once we cross over that crucial threshold to have a colony that is politically independent.Would that be your worst-case scenario? Look, I'd like a space economy. I would like there to be some space hotels. Maybe we do some manufacturing, see what happens.Space infrastructureSo I'm assuming that was your worst-case scenario. Do you have a positive space story? One that concerns you far less, at least?Tourism, within the larger scheme of things, is really kind of a trivial pursuit.In terms of space resources, we're talking here primarily about the extraction of valuable metals from asteroids. That's a civil technology that would require the ability to alter the orbits of masses of asteroidal material and asteroids in the solar system. Presumably, you're going to insert these bodies into Earth orbit. So you'll have to have highly precise capabilities to alter their orbits. And of course, we would also want to develop technologies to alter their orbits so that we can avoid them colliding with the Earth (although that's not really a short-term problem).And so I look at this as a civil technology and I say, “How distinctive is this from the military technology?” And the answer is, it's almost none. It's a question of the trajectory. Once you have the technologies to alter the trajectories of asteroid-size bodies in the solar system, you're going to have to tap into a violence capacity that will be millions of times greater than all nuclear weapons combined. So I say that allowing private enterprise to develop asteroidal mining, as seems to be the preferred American scenario, is kind of like allowing private enterprise to develop and have hydrogen bombs. It's just not a good idea because of the enormous destructive potential.Many of the scenarios for near-Earth envision giant infrastructures in orbit. A favorite is collecting solar energy from orbit — we have this problem of immense importance with regard to the carbon loading of the atmosphere, and there's lots of energy that can be collected in space and beamed down to the Earth.But thinking about that as an economic proposition, or even an ecological proposition, is insufficient. We have to also think about it as a political and military proposition. My view is that it's not going to be possible to develop infrastructures in near-Earth space until we have overcome interstate rivalry. Think about the Chunnel between France and Britain. It's unthinkable in a situation of interstate rivalry.So it could be that the creation of this apparatus — I call this Orbita — would require the pacification of interstate relations. That's potentially good news. But the potentially bad news is that whoever controls Orbita would be able to control the Earth because these enormous quantities of energy could be readily weaponized to shoot down anything coming up from the Earth. So it's like we have a village and we're going to build a big castle next to it. We're going to have to expect that the village will get dominated by the castle.Hedging existential riskRegarding inter-solar system conflicts, why would you be more worried about war with evolved insectoid humans than about an asteroid hitting the Earth? How do you begin to figure out which is riskier?I'm worried about the asteroid-hitting-the-Earth scenario. I'm not sure how to figure out which of those scenarios is more likely. But I know the one has happened before, and they keep telling us that it's only a matter of time before it'll happen again.That's right, it is just a matter of time. It might be a long time before a significantly large one strikes. But you make a very good point, and you've asked me if I have a positive vision of space. I lay out what I call an Earth-oriented space program, which does include the development of techniques to deflect asteroids. But it should only be done by a consortium of states and should not be coupled with the development of economic exploitation.And look, if we do have asteroidal mining, then I think it's very unlikely that actors of magnitude on the Earth would support colonization. If this is the great bonanza of mineral resources, the last thing we would want to do is to create a rival — Mars, in particular — that would be in a much more proximate location to exploit these. So I think that as the prospect of Martian colonization starts to become a real possibility, these types of concerns are going to be increasingly evident to people. This is what I refer to as the second great debate about solar-orbital space: What should we do? And I think that as it becomes real, these objections will become increasingly compelling to large numbers of actors on the Earth.What you're ideally recommending is, I suppose, you would have us wait to go into space almost completely until we have a much different geopolitical situation here on Earth. And it seems like we're going in just the opposite direction — it seems like we're actually having intensive competition. So I would assume you would find that worrying.Yeah. I think that the directions that we're headed in are largely disaster-prone. And of course, one of the directions that we're going in that never gets talked about is continuing to modernize, replace, and improve the nuclear weapon delivery system. That is, as I said earlier, this major space program that we don't acknowledge as such. And the United States has, during the Trump era, declared the objective of dominating space. And this is something that has long been talked about by various military visionaries. But this was an important threshold that we have crossed.The SpaceX Corporation, as I'm sure everyone listening to this podcast knows, has lowered significantly the cost of accessing near-Earth orbit — by a kind of order of magnitude, perhaps. And they have these plans to build even larger rockets that they make claims about even further reducing the cost of accessing near-Earth orbit. And this is widely hailed as a great advance.I look at this, and I say, “Well, it's going to lower the cost of doing stuff in space.” And the question then is: Which of this stuff is going to get done? And of course, immediately the military is interested. The idea that we can dominate space is going to depend upon having the capacity to put significant mass into orbital space.So I think that we have been misperceiving the overall character of this environment. We've been misrepresenting the actual effects to date. And when we get rid of this “Oh it's going to all be so wonderful” mentality and critically examine what has happened, what is happening, and what is likely to happen, we have a very different picture.And I want to emphasize that I am not a Luddite. I am not opposed to technology generally, but humanity over the course of the 20th century has started to develop technologies that are extremely potent, double-edged swords. And the question that we have to confront is whether we have the ability to steer the use of these technologies so that we get the benefits without getting the downsides. And our record so far is not very promising.But we haven't used nuclear weapons. In fact, the United States reached agreements with the Soviet Union to reduce nuclear weapons. And you could say we've even over-corrected because our fear of radiation has led us to abandon nuclear power. So hasn't the record shown that we have been able to handle these weapons and that, if anything, we've been overly cautious when it comes to dealing with new technologies that could have a great benefit?Well, that would be a long conversation. And with regard to nuclear weapons, we have a fundamental epistemological problem here: What is the probability of nuclear war?During the Cuban Missile Crisis, John Kennedy said he thought it was between one-in-three and one-in-two. And knowing what we now know about the Cuban Missile Crisis, it was clearly more likely than that. So do we look at the Cuban Missile Crisis and say, “Hey, no problem here”? Or do we look at it and say, “We were really lucky”? There's a fundamental disagreement about nuclear weapons that we really can't resolve by appealing to the empirical evidence. And that fact alone should be very sobering to us.But I think that if you looked at this without any sort of theoretical presumptions and said, “Is it really a good idea to have thousands of high-yield thermonuclear weapons prepared for nearly instant use?” That strikes me as a bad idea. And, you know, some people say, “Well, that's what saves us.” But look at this as a case study: The only way we can deal with nuclear weapons is by building large numbers of them and have them posed for immediate use? That strikes me as a very limited adjustment.So do you think that ultimately we're going to have to get lucky again? There seems to be a lot more interest in space. And that interest is obviously among countries who have major disagreements and who view space as both an economic opportunity and as a military necessity. So it seems like the scenario going forward is a multipolar space race with an uncertain conclusion.That's right. That's clearly where we're headed now.One of the important things to remember about space is the basic geography. We think that we've left the planet when we have gone beyond the atmosphere, but I argue that this is a geographic error — the area around the terrestrial Earth that is dominated by the Earth's gravitational and magnetic fields is really part of the planet. I call that the “astrosphere.” We have the lithosphere, the hydrosphere, the atmosphere, and also the astrosphere.We tend to think of the astrosphere as being incredibly large. And of course space generally, even solar space, is mind-bogglingly large. But the astrosphere, and particularly the lower parts of it where almost all activities have occurred, is in practical terms actually smaller than the atmosphere. And that's because, while the volume has gone up, the velocities that are necessary to operate there have gone up by even greater amounts. And so effective distance within the astrosphere is much lower than it is within the atmosphere. So people have fundamentally misperceived this environment — it actually is small.And then you go back into the earlier predictions about space: No one thought about space debris. No one said, “Oh yeah, this is going to become quickly polluted in ways that will be very problematic.” It's part of this tendency to use bad analogies. People say, “Oh well, the ocean. The Europeans went out onto the ocean, centuries of expansion occurred and great wealth and prosperity and so forth resulted.” But this is a very misleading analogy.To start with, the ships that have existed since oceanic transportation developed are not shuttling around the ocean at high velocities. Half the satellites that have been put into orbit are still there — dead, hurtling around at very high velocities, over time breaking up and colliding with things. So if you want an ocean analogy, it's more like the Mediterranean or the Caribbean, or maybe even the Aral Sea. For a frontier that has barely been opened, we already have this level of degradation that greatly exceeds what we have with the ocean. So there's been this basic misperception of this domain.Principles for space policyTo wrap up, what would you advise? You view this as the beginning stage of something that could prove very dangerous. Better to figure out now what we need to do and talk with other countries so we can figure this out sooner rather than later. So then what would you advise the United States to do as far as space policy?Well, I lay out an Earth-oriented space program. And the first step would be to continue undoing the ballistic-missile-ization of the nuclear delivery system. One of the implications of that argument is that we have another space program that we don't recognize as a space program: what we call nuclear arms control. It has never been primarily about nuclear weapons, per se. It's been about delivery vehicles, most of which have been ballistic missiles. And as you say, at the drawdown at the end of the Cold War, we made important steps in this direction. What we call nuclear arms control is to a first approximation space weapons arms control. It's our most successful space program in the sense of its benefit to avoid catastrophic and existential disasters. So the first step would be to continue that, to complete that revolution.Then we should use space for Earth habitability studies. We should do space science on a larger scale in virtually every dimension. If we want to have humans in space, that's built on our other important historical accomplishment, the International Space Station. Instead of a free-for-all for lunar resources, let's build an international science cooperative base on the moon with the Russians and the Chinese involved as well.And insofar as asteroids striking the Earth are a potential problem, we need to do better surveys. And if we want to have demonstrations, this should only be done on a cooperative basis. We do not want this technology to get weaponized. That's something very important.As for the colonization scenario, we should relinquish that. We should draw a red line. No colonies. We do not want to pursue them. And the reason is that we have got the story backward. The dinosaurs, they tell us, were wiped out because they didn't have a space program. I say the dinosaurs lasted 200 million years because they didn't have a space program. And you say, “Ah, the Earth — all of our eggs are in one fragile basket.” I say, if we have multiple space colonies, we'll have dispersed eggs, which will be subject to rock smashing, which will be easy and likely.So we've got to get the narrative right. We have to stop thinking about this in this sort of a wonder-struck manner. There's this famous quote that the advocates are always using from Konstantin Tsiolkovsky, the great Russian visionary: “Humanity is in its cradle, and humanity cannot stay in its cradle forever.” The implication being, we have to leave the cradle of the Earth and expand into the cosmos. I look at that little quote and I say, “Well, we also recognized that the ideas that infants have in their cradle, that children have, are not good guides for adult behavior.” It's essentially an infantile vision, and we need a much more sober vision. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit fasterplease.substack.com/subscribe

Un intrépido equipo de astronautas y pilotos vuelan en un jet de alta velocidad alrededor de la tierra, para establecer el récord de circunnavegación desde un polo hasta el otro. Su aventura comenzará desde el mismo lugar desde el que se lanzó el cohete Apollo11 hacia la luna 50 años antes, y supone un tributo al pasado, el presente y el futuro de la exploración espacial, rompiendo los límites de lo que se creía posible.

Agradece a este podcast tantas horas de entretenimiento y disfruta de episodios exclusivos como éste. ¡Apóyale en iVoox! Baby-Órbita es un tipo de podcast realizado enteramente por niños de menos de 12 años (con la excepción de un niño cuarentón con barba, pero es que alguien debe dirigir esto). La visión que se ofrece del tema escogido es el propio de personitas de esta talla y experiencia vital. A veces, sorprende cómo ven los niños las pelis y las series que vemos los adultos. Hoy, con Elia de 6 años, empezaremos hablando de la película El Gato con Botas: El Último deseo y a partir del personaje del Lobo Feroz, terrorífico entre los niños, nos pondremos a hablar de cuentos infantiles que dan mal rollito y otros miedos infantiles. El programa, no obstante, no da miedo y es ideal para escuchar con los más pequeños. Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

Gustavo Cosenza y Nicole Leon son el director-guionista y la productora de este increíble y pionero proyecto cinematográfico costarricense de ciencia ficción. Y ellos se sentaron a hablar del proyecto acá en Hablemos Paja!!! En esta primera parte hablamos del porqué de este proyecto y porqué ciencia ficción, entre otras cosas. SIN SPOILERS POR SUPUESTO

Agradece a este podcast tantas horas de entretenimiento y disfruta de episodios exclusivos como éste. ¡Apóyale en iVoox! Baby-Órbita es un tipo de podcast realizado enteramente por niños de menos de 12 años (con la excepción de un niño cuarentón con barba, pero es que alguien debe dirigir esto). La visión que se ofrece del tema escogido es el propio de personitas de esta talla y experiencia vital. A veces, sorprende cómo ven los niños las pelis y las series que vemos los adultos. Hoy, con Bea de 9 años, reseñaremos WEDNESDAY (Miércoles) una serie poco infantil que, curiosamente, ha hecho gracia a muchos niños. ¿? Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

Host David Harlow chats with Patty Riskind, CEO of Orbita, to gain some insight into pain points for patients and providers and potential approaches to solving some intractable problems, through the pandemic and beyond. What does it mean for conversational AI to be the connective tissue between healthcare organizations and patients? To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Dmitry Kibkalo is an entrepreneur, investor, founder of the Orbita venture studio. Founder and ex-owner of the Mosigra chain of stores. Graduate of the Mechanics and Mathematics of Moscow State University and Stanford GSB. In 2013, he was included in the Forbes list of young entrepreneurs who have created a serious business under 33 years old. In 2019, he sold Mosigra and launched more than 10 startups, including: Vox - a social network on voice messages, Cabinet.fm - a service for consultants, Festa - a platform for party games, Meteor - a network of football schools, Zvezda - a network dance schools and others. Author of the books “Business as a Game” (winner of the “Business Book of the Year” award) and “Business on Your Own”, Board Game “Jackal”, “Day of Leaders”, “Yorsh”. FIND DMITRY ON SOCIAL MEDIA LinkedIn | Facebook | Instagram | Telegram ================================ SUPPORT & CONNECT: Support on Patreon: https://www.patreon.com/denofrich Twitter: https://twitter.com/denofrich Facebook: https://www.facebook.com/denofrich YouTube: https://www.youtube.com/denofrich Instagram: https://www.instagram.com/den_of_rich/ Hashtag: #denofrich © Copyright 2022 Den of Rich. All rights reserved.

Después de 10 meses de vuelo en el espacio, la prueba de redirección de doble asteroide (DART) de la NASA, la primera demostración de tecnología de defensa planetaria del mundo, ha impactado satisfactoriamente esta madrugada con su objetivo. Tal y como informa la propia NASA, DART apuntó a la pequeña luna Dimorphos, un cuerpo pequeño de solo 160 metros de diámetro. Orbita alrededor de un asteroide más grande de 780 metros (2,560 pies) llamado Didymos. Ninguno de los asteroides representa una amenaza para la Tierra. Juan Luis Cano, responsable de Defensa Planetaria del Centro de Coordinación NEO de la Agencia Espacial Europea, calibra la magnitud de esta operación, que será completada con la Misión Hera de la ESA.

F-Cell storms the Orbita compound and facilitynegativemodifier@gmail.comSupport the show on Patreonwww.negativemodifier.comHawthrone's Crusade is a Delta Green actual play campaign and sequel campaign to The J-Cell Files.Intro: Wanting 1105 - Music by AlexisOrtizSofield from PixabayExtro: Smokey Light 811 - Music by 1tamara2 from PixabayLicensed under Creative Commons BY Attribution 4.0 License

Who's up for one last Green Box before F-Cell makes their move on the allegedly abandoned Orbita facility?negativemodifier@gmail.comSupport the show on Patreonwww.negativemodifier.comHawthrone's Crusade is a Delta Green actual play campaign and sequel campaign to The J-Cell Files.Intro: Wanting 1105 - Music by AlexisOrtizSofield from PixabayExtro: Smokey Light 811 - Music by 1tamara2 from PixabayLicensed under Creative Commons BY Attribution 4.0 License

Nil Agra, Arianna Nutt, Kedny Silva e Flávio Andrade participam do Venus Fora de Órbita. Bate papo, jogos, comidas e muita risada te esperam nesse especial